In:
Blood, American Society of Hematology, Vol. 140, No. 5 ( 2022-08-04), p. 516-520
Abstract:
Li et al delineate a novel technique for assessing measurable residual disease (MRD) by the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD in LSCs provides a better prediction of outcome than standard multiparameter flow cytometry.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.2021014604
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2022
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Permalink